Stockscreener 앱 받기
76.28
1.03%
-0.79
전일 마감가:
$77.07
열려 있는:
$76.79
하루 거래량:
6.66M
Relative Volume:
1.54
시가총액:
$236.57B
수익:
$56.53B
순이익/손실:
$8.32B
주가수익비율:
28.46
EPS:
2.6798
순현금흐름:
$8.49B
1주 성능:
-4.12%
1개월 성능:
-4.10%
6개월 성능:
-0.05%
1년 성능:
-3.32%
1일 변동 폭
$76.16
$77.27
1주일 범위
$76.08
$78.52
52주 변동 폭
$61.24
$82.41
아스트라제네카 ADR Stock (AZN) Company Profile
명칭
Astrazeneca PLC
전화
44 20 3749 5000
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
76.28 | 238.96B | 56.53B | 8.32B | 8.49B | 2.6798 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
AstraZeneca PLC $AZN is Professional Advisory Services Inc.'s 9th Largest Position - MarketBeat
Wealth Enhancement Advisory Services LLC Buys 12,427 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Short Interest Update - MarketBeat
Oliver Lagore Vanvalin Investment Group Makes New $811,000 Investment in AstraZeneca PLC $AZN - MarketBeat
Phillips Wealth Planners LLC Acquires 3,447 Shares of AstraZeneca PLC $AZN - MarketBeat
Aug Setups: Does AstraZeneca PLC Depositary Receipt have a sustainable dividend2025 Stock Rankings & Entry Point Confirmation Alerts - خودرو بانک
Astrazeneca (AZN) Stock Slides as Market Rises: Facts to Know Before You Trade - Nasdaq
Momentum Shift: What is AstraZeneca PLC Depositary Receipts valuation compared to sectorProduct Launch & Technical Pattern Alert System - khodrobank.com
RSI Check: Can ZYBT withstand a market correctionJuly 2025 Recap & Fast Moving Market Watchlists - khodrobank.com
AstraZeneca: Consistent Growth And Upcoming Catalysts Make This A Buy (NASDAQ:AZN) - Seeking Alpha
Community Trust & Investment Co. Increases Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Purchased by Swedbank AB - MarketBeat
Procyon Advisors LLC Decreases Stake in AstraZeneca PLC $AZN - MarketBeat
3,345 Shares in AstraZeneca PLC $AZN Purchased by Ashton Thomas Private Wealth LLC - MarketBeat
Risk Check: Whats the outlook for AstraZeneca PLC Depositary Receipts sector2025 Trade Ideas & Precise Trade Entry Recommendations - خودرو بانک
A pharma giant with star quality - Investors' Chronicle
Japan Auto-Injectors for Glp-1 Receptor Agonists Market Outlook Report 2025-2038: Convenience and Compliance Boost Adoption As At-home Delivery Methods is Growing - GlobeNewswire Inc.
AstraZeneca Says FDA Approves Airsupra Label Update to Include Mild Asthma Benefits - MarketScreener
AstraZeneca reports Saphnelo demonstrates reduction in disease activity - Yahoo Finance
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
Lineweaver Wealth Advisors LLC Acquires Shares of 8,124 AstraZeneca PLC $AZN - MarketBeat
Channel Wealth LLC Buys 14,898 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca’s Saphnelo SC shows reduction in disease activity in SLE trial - Clinical Trials Arena
Acadian Asset Management LLC Lowers Position in AstraZeneca PLC $AZN - MarketBeat
Voya Investment Management LLC Purchases 443,795 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial - Benzinga
AstraZeneca’s Fasenra RESOLUTE Failure Highlights The Limits Of Biologics In COPD - insights.citeline.com
AstraZeneca's (AZN) Fasenra COPD Trial Misses Key Endpoint - GuruFocus
AstraZeneca fails to meet main goal in lung disease trial (AZN) - Seeking Alpha
AstraZeneca (AZN) Advances Saphnelo Injectable in Key Phase 3 Tr - GuruFocus
AstraZeneca posts late-stage trial win for injectable Saphnelo in SLE - Seeking Alpha
AstraZeneca reports positive Phase III results for Saphnelo in lupus trial By Investing.com - Investing.com South Africa
Investment crisis: AstraZeneca halts $271m UK expansion - BioXconomy
Assessing AstraZeneca Shares After Investment Pause in Britain and Recent Price Slide - Yahoo Finance
AstraZeneca reports positive Phase III results for Saphnelo in lupus trial - Investing.com
AstraZeneca (AZN) Reports Positive Phase III TULIP-SC Trial Resu - GuruFocus
AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease - Stocktwits
AstraZeneca Says Phase 3 Trial of Fasenra in COPD Fails to Meet Primary Endpoint - MarketScreener
Canandaigua National Bank & Trust Co. Has $1.38 Million Stake in AstraZeneca PLC $AZN - MarketBeat
Howe & Rusling Inc. Sells 35,353 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca says Fasenra misses main goal in COPD trial By Investing.com - Investing.com Nigeria
AstraZeneca Asthma Drug Fails COPD Study for a Second Time - Bloomberg.com
AstraZeneca lupus drug Saphnelo shows promise in self-injection trial - Proactive Investors
AstraZeneca's asthma drug fails 'smoker's lung' study - Reuters
AstraZeneca says Saphnelo met primary endpoint in Tulip-SC - MarketScreener
AstraZeneca's Systemic Lupus Erythematosus Medicine Meets Primary Endpoint in Late-stage Trial - MarketScreener
AstraZeneca's Fasenra Fails to Meet Primary Endpoint in Pulmonary Disease Trial - MarketScreener
AstraZeneca's asthma drug fails main goal of COPD study - MarketScreener
AstraZeneca : Saphnelo met primary endpoint in TULIP-SC - MarketScreener
AstraZeneca : Update on RESOLUTE Phase III trial - MarketScreener
Retail Trends: Should I hold or sell AstraZeneca PLC Depositary Receipt now2025 Analyst Calls & Fast Gaining Stock Reports - khodrobank.com
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):